Bausch + Lomb’s $75.5M CEO Exit Is What Control Really Looks Like
Brent Saunders was gone from Bausch + Lomb overnight — with $75.5 million in cash. That is not a succession plan. It is a controlling shareholder making the call.
Brent Saunders was gone from Bausch + Lomb overnight — with $75.5 million in cash. That is not a succession plan. It is a controlling shareholder making the call.
On October 12, Bausch + Lomb announced that Saunders had “mutually agreed” with the board to leave as CEO and director, effective immediately. Thomas J. Appio — chairman of Bausch + Lomb and CEO of its controlling shareholder, Bausch Health — became interim CEO while keeping his day job. Saunders’ separation agreement was dated October 11. One day you are the CEO. The next day the parent company’s CEO is in your chair. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1860742/000095010326015460/dp254863_8k.htm))
Here is the bit most corporate press releases politely step around: when one shareholder controls the company, the boardroom is not a democracy. It is a hierarchy with nicer stationery.
The $75.5 million price of an immediate exit
Saunders will receive a $75.5 million lump-sum cash payment, plus up to $50,000 for legal fees and continued access to company health plans for two years. In exchange, his outstanding equity awards were cancelled and forfeited. He will provide up to 90 days of transition help without additional pay, and remains bound by confidentiality, non-compete, non-solicitation, non-disparagement and cooperation obligations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1860742/000095010326015460/dp254863_8k.htm))
That is a serious cheque. But it is also serious finality.
The cash figure will attract the outrage because it is easy maths: most people will never earn a fraction of it despite working their guts out for decades. Fair enough. But the more useful question for founders, investors and operators is not whether $75.5 million feels obscene. It is: what did Bausch + Lomb buy for it?
It bought certainty.
No extended executive soap opera. No former CEO hanging around as executive chair, poisoning the water and second-guessing the replacement. No drawn-out public power struggle. No ambiguity over who runs the asset now. Saunders left the CEO job and the board on October 12. Appio took over that same day.
That speed is expensive, but indecision can be vastly more expensive. I have watched businesses lose years because the board wanted a clean leadership break without being willing to pay for one. They end up with the worst of both worlds: a distracted chief executive, anxious staff, factions at the top and a market that smells blood.
Bausch + Lomb chose the costly clean break.
Thomas Appio is not an outside caretaker
Calling Appio an “interim” CEO is technically accurate. It is also slightly misleading.
Appio has been Bausch Health’s CEO since 2022. Bausch Health is Bausch + Lomb’s controlling shareholder. He became Bausch + Lomb chairman in August 2026, after replacing Saunders in that chair role. Before all of that, Appio had spent years inside Bausch + Lomb: he joined in 2010 as managing director for China and became president of Bausch + Lomb International in 2016. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1860742/000095010326015460/dp254863_ex9901.htm))
This is not a board ringing an executive-search firm and hoping for the best. This is the parent company putting its own operator directly in charge of the subsidiary.
Reuters reported that Bausch Health owns roughly 87% of Bausch + Lomb. That makes the logic brutally simple. Bausch + Lomb may trade publicly, but control is concentrated. Minority shareholders get a listed share; Bausch Health gets the steering wheel. ([boursorama.com](https://www.boursorama.com/bourse/actualites/bausch-lomb-le-directeur-general-saunders-quitte-ses-fonctions-le-president-du-conseil-d-administration-appio-nomme-directeur-general-par-interim-5fea229b5104c40c5ac85eef14661eaa))
That distinction matters because plenty of investors still look at a public-company board and assume the normal rules apply. They do not, not in the same way. In a controlled company, the real question is not “What does the board want?” It is “What does the controller need?”
And right now, Bausch Health appears to want a tighter grip on an asset it spun out publicly in 2022 while retaining control.
This was abrupt — and that is the whole story
Saunders returned as Bausch + Lomb CEO in 2023 after an earlier stint from 2010 to 2013. He had also led Allergan until AbbVie acquired it for $63 billion in 2020. This was not a rookie found out by the job. It was a seasoned health-care executive, brought back to run an eye-care company he knew well. ([boursorama.com](https://www.boursorama.com/bourse/actualites/bausch-lomb-le-directeur-general-saunders-quitte-ses-fonctions-le-president-du-conseil-d-administration-appio-nomme-directeur-general-par-interim-5fea229b5104c40c5ac85eef14661eaa))
The company gave no detailed reason for his departure. Its filing says it was not due to a dispute or disagreement over operations, policies or practices. That language is standard, and it tells us very little beyond the fact that the lawyers have done their work. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1860742/000095010326015460/dp254863_8k.htm))
What we can say is this: the timeline is hard to ignore.
In August, Appio took over as board chairman. In October, Saunders was removed as CEO and director, Appio became interim CEO, and Bausch + Lomb disclosed that it expected to raise full-year 2026 adjusted EBITDA guidance after preliminary third-quarter results. The business may be performing well enough to lift guidance, but its leadership structure was still changed at speed. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1860742/000095010326012223/dp251654_8ka.htm?utm_source=openai))
That is the part many managers get wrong. They assume strong operating numbers buy them safety. They do not.
Performance matters enormously. But in a controlled business, alignment matters too: alignment with the owner’s capital plan, strategic timetable, appetite for risk, leadership style and desired level of direct control. If any of those change, yesterday’s capable CEO can become today’s inconvenient one.
That is not necessarily unfair. Ownership should mean something. But don’t confuse it with the fluffy corporate myth that results alone determine who stays.
The overlooked angle: this is not really about one executive
The easy take is that Bausch + Lomb paid $75.5 million to move on from Brent Saunders.
The more important take is that Bausch Health is simplifying command over an asset that remains strategically important.
Bausch + Lomb and Bausch Health said they expect to provide more details when they report third-quarter results on October 28, 2026. The company’s preliminary update said it expects to raise 2026 adjusted EBITDA guidance, citing strong third-quarter performance and expectations for the rest of the year. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1860742/000095010326015460/dp254863_ex9901.htm))
So this is not a classic rescue mission where a board sacks a CEO after a disastrous quarter and wheels in someone with a fire hose. It looks more like an owner deciding that the next phase requires one chain of command.
That can be smart. Dual layers of authority are a pain in the arse when a parent company controls the asset anyway. Separate CEO, separate board leadership, separate priorities, separate investor messaging — eventually somebody asks why the organisation is paying for complexity it does not need.
But there is a risk too. Appio is now CEO of Bausch Health and interim CEO of Bausch + Lomb. That can create speed and alignment in the short term. It can also create management bandwidth problems and make it harder for outside shareholders to know where the parent’s interests end and the subsidiary’s begin.
The board’s next real test is not whether Appio can keep the seat warm. It is whether it runs a credible process for a permanent CEO, defines what independence actually means under a controlling shareholder, and gives investors a clear reason to believe Bausch + Lomb is being built for more than convenience at the parent level.
Don’t romanticise succession planning
Every company claims to have succession planning. Most of them have a slide deck, a few names in a confidential file and absolutely no appetite to make a difficult decision until the decision makes itself.
Real succession planning looks different. It means knowing, before the crisis, who can run the business on Monday morning. Appio could. That is why he is there.
But a proper succession plan is not merely having a replacement. It is having a replacement whose mandate is clear.
Is Appio there to stabilise the company for three months? To run it permanently? To prepare it for a capital-markets move? To appoint a new operator while Bausch Health tightens strategic control? We do not know yet.
And that uncertainty is where markets get twitchy. Reuters reported Bausch + Lomb shares fell more than 7% after the news. Investors can tolerate change. What they hate is unexplained change, especially when a proven CEO exits immediately and the controller installs its own CEO as interim successor. ([boursorama.com](https://www.boursorama.com/bourse/actualites/bausch-lomb-le-directeur-general-saunders-quitte-ses-fonctions-le-president-du-conseil-d-administration-appio-nomme-directeur-general-par-interim-5fea229b5104c40c5ac85eef14661eaa))
What this means for you
If you are a founder, stop treating governance as legal housekeeping. Write down who can remove you, under what conditions, and what happens to your equity, information rights and reputation if it occurs. Do it before the company is valuable enough for everyone to start lying politely.
If you are an operator, build a business that can survive without you — but never assume that makes you irreplaceable. Keep your board relationships direct. Understand the owner’s strategic agenda. Delivering numbers is essential; being strategically misaligned is still fatal.
If you are an investor, read the control structure before you fall in love with the ticker. A public share does not always come with public-company influence. Find out who appoints the board, who controls votes, who can reshape leadership overnight, and whether minority investors are buying into a business or simply renting exposure to somebody else’s decisions.
And if you run a board, learn the uncomfortable lesson here: if you need to make a clean leadership break, make it clean. Do not drag it out to avoid an ugly number. Pay what is necessary, define who is in charge, communicate what happens next, then get back to building the bloody business.
Bausch + Lomb’s $75.5 million exit package is not the real headline. The real headline is that control, when it is concentrated, eventually gets used.